Search Results

Terra Clean Energy Receives Exploration Permit for Marysvale Uranium Project in Utah, USA

Terra Clean Energy Corp. recently announced that it has received the relevant permit from the Utah Division of Oil, Gas and Mining under the Utah Department of Natural Resources to carry out planned exploration work at its wholly-owned Marysvale Uranium Project. Under the approved work plan, the company will construct 5 drill pads to support subsequent diamond core drilling, and excavate 7 exploration trenches to expose and evaluate known uranium-bearing outcrops. Terra stated that this permit represents a significant milestone in advancing this historic uranium project. The trenching work will help the company's technical team map mineralized structures, collect samples, and validate existing geological interpretations. The results will...

2026-08-18

Turkey's TR-2 Research Reactor Receives Operating License

The Turkish Nuclear Regulatory Authority has issued an operating license for the TR-2 research reactor at the Istanbul campus of the Nuclear Energy Institute under the Turkish Energy, Nuclear and Mineral Research Agency (TENMAK). The license was issued pursuant to the Authority's Decision No. 2026-34/3 dated August 6, 2026. Following the review and evaluation of TENMAK's application documents, the Turkish Nuclear Regulatory Authority authorized the agency to carry out the activities required for the transition of the TR-2 research reactor from its current status to the operational phase. TR-2 is located at the Istanbul campus of TENMAK's Nuclear Energy Institute, with an approved thermal power of 5 megawatts. The facility is a research reactor and is not a nuclear facility primarily intended for power generation. According to...

2026-08-17

Finland's Onkalo Spent Nuclear Fuel Final Disposal Facility Expected to Receive Operating License by Year-End

Finland's spent nuclear fuel final disposal project has entered the critical stage of operating license review. The Radiation and Nuclear Safety Authority of Finland (STUK) issued a statement saying that the design and emergency response procedures of the Onkalo final disposal facility meet the safety requirements for granting an operating license. The Finnish government is expected to decide whether to approve the facility's operation before the end of the year. Onkalo is located on Olkiluoto Island in southwestern Finland. "Onkalo" means "cave" in Finnish. If licensed and operational, the facility will become the world's first deep geological final disposal facility for spent nuclear fuel from nuclear power plants, serving as a reference for other countries considering similar facilities...

2026-08-14

U.S. Company Proposes Americium-241 Radioisotope Heating Solution for Spacesuits, Receives Early NASA Research Support

U.S.-based Zeno Power Systems has proposed a radioisotope heating concept for lunar extravehicular activities, planning to use Americium-241 (Am-241) to provide continuous passive warmth for astronauts during lunar nights and in permanently shadowed regions. The proposal has been selected for this year's NASA Innovative Advanced Concepts (NIAC) program, with the potential to receive up to $175,000 in early-stage research funding. The lunar surface environment is one of the key challenges for long-duration crewed missions. Data shows that lunar nights can last approximately two weeks, and extreme low temperatures will limit the duration of astronaut extravehicular activities in shadowed areas and at night. Even with new-generation spacesuits, their cold resistance remains limited...

2026-08-13

University of Missouri Receives $1 Million Grant to Research New FLASH Radiotherapy System

On August 11, researchers at the University of Missouri School of Medicine received a $1 million grant from the National Institutes of Health to study a new technology in cancer radiotherapy—the TheryQ FLASHKNiFE system. The project is funded through June 2027. A long-standing challenge in cancer treatment is how to kill tumor cells while protecting surrounding healthy tissue as much as possible. Existing radiotherapy can already achieve millimeter-level precision, but radiation damage and related side effects still limit the dose patients can safely receive. Unlike conventional approaches, FLASH radiotherapy does not primarily alter the direction of radiation beams, but instead delivers irradiation in an extremely short time at an ultra-high dose rate...

2026-08-12

Brazil's IRD Radiometric Metrology Laboratory Receives CTBTO Certification, Joins International Nuclear Test Monitoring Network

The Radiometric Metrology Laboratory of Brazil's Institute of Radiation Protection and Dosimetry (IRD/ANSN) has recently received certification from the Comprehensive Nuclear-Test-Ban Treaty Organization (CTBTO), officially qualifying it to join the international verification system. The certification was granted following an on-site audit conducted by the CTBTO in Rio de Janeiro from June 16 to 25, marking the Brazilian laboratory as the 15th certified unit among the 16 treaty-designated radionuclide laboratories. The certification primarily confirmed that the laboratory meets CTBTO requirements in high-precision analysis, result reliability, data traceability, and standardization of technical procedures. The audit covered sample reception and preparation, equipment calibration, result interpretation,...

2026-08-12

Russia's MEPhI Receives Over 1 Billion Rubles in Funding for Two Domestic Scientific Instrument Projects

The Russian Ministry of Science and Higher Education will allocate 2.81 billion rubles to support the development of eight types of domestically produced scientific research equipment. According to the results of an additional competitive selection, the funds are planned to be disbursed from 2026 to 2028, with six universities and research institutions set to receive support. Among them, the National Research Nuclear University MEPhI (Moscow Engineering Physics Institute) will receive the largest share, with two projects totaling slightly over 1 billion rubles in funding. Under the arrangement, MEPhI will receive 591 million rubles for the development of a tandem quadrupole time-of-flight mass spectrometer (QTOF MS), and an additional 433 million rubles for the atom probe tomography project. Both projects have previously been approved by the Russian Academy of Sciences and included in...

2026-08-12

Korea's Naju Artificial Sun Research Facility Expected to Receive Preliminary Feasibility Study Results in September

The project to build the Naju Artificial Sun research facility in Korea is expected to receive the results of the national preliminary feasibility study in September. With a total investment of approximately 1.2 trillion KRW, the project plans to construct large-scale nuclear fusion research and demonstration infrastructure in Wangok-myeon, Naju City, South Jeolla Province, and is regarded by local governments as a key pillar in the future industrial layout of the South Jeolla–Gwangju Integrated Special Zone. The Ministry of Science and ICT (MSIT) designated the "Nuclear Fusion Core Technology Development and Strategic Infrastructure Construction Project" as a national R&D project and included it in the preliminary feasibility study on January 30. According to the previous schedule, the evaluation period was approximately seven months. The results were originally expected to be announced in August, but...

2026-08-11

Morehead State University Receives $50,000 Grant to Support Nuclear Medicine Technology Bachelor's Program

Morehead State University in the United States recently received a $50,000 grant to strengthen its Bachelor of Science in Nuclear Medicine Technology program, supporting the university's efforts to train medical imaging professionals for Kentucky's healthcare system. The funding was provided by the Kentucky Board of Medical Imaging and Radiation Therapy and administered by the Kentucky Council on Postsecondary Education. The project funds were awarded through a competitive bidding process, with a focus on supporting nuclear medicine technology education programs in Kentucky, aiming to increase the number of qualified professionals entering the state's healthcare industry. The newly established nuclear medicine technology undergraduate program under Morehead State University's Department of Imaging Sciences will prepare students in the field of medical imaging...

2026-08-11

ITM Receives Complete Response Letter from FDA for ¹⁷⁷Lu-edotreotide New Drug Application

Radiopharmaceutical biotechnology company ITM Isotope Technologies Munich SE (ITM) announced on August 10 that it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on August 7, 2026, regarding the New Drug Application (NDA) for its investigational drug ¹⁷⁷Lu-edotreotide (ITM-11). The drug is intended for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

2026-08-11

Former U.S. President Biden's Prostate Cancer Progress: Has Received Radiation Therapy and Hormone Therapy

The health condition of former U.S. President Joe Biden has recently drawn renewed attention. In an interview video, his son Hunter Biden stated that after Biden was diagnosed with prostate cancer, the cancer cells had metastasized, spreading to the bones and other parts of the body, and described the process as extremely painful. According to relevant information, Biden, now 83 years old, disclosed in May 2025 that he had been diagnosed with an aggressive form of prostate cancer, with cancer cells confirmed to have spread to the bones at that time. In October, a Biden spokesperson announced that he was undergoing radiation therapy and hormone therapy. Radiation therapy is one of the common nuclear technology medical applications in tumor treatment, primarily using ionizing radiation on tumor tissue to...

2026-08-10

Grand Pharma's FAP-targeted diagnostic radiopharmaceutical GPN01530-2 receives FDA Fast Track designation

On August 9, 2026, Grand Pharmaceutical issued a voluntary announcement stating that its self-developed global innovative radionuclide drug conjugate GPN01530-2 has recently been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the diagnosis of solid tumors. Previously, the product had already been approved by the FDA to conduct Phase I/II clinical studies for the diagnosis of solid tumors. GPN01530-2 is a small-molecule radionuclide drug conjugate (RDC) targeting fibroblast activation protein (FAP). Data shows that FAP is not expressed or is lowly expressed in normal tissues, but is highly expressed in tumor-associated fibroblasts within the tumor microenvironment of various cancers, and is considered a novel specific target in the field of tumor diagnosis and treatment...

2026-08-10

Ukraine's Radon Association Receives EU-Assisted Equipment to Enhance Operational Reliability of IASRM Radiation Monitoring System

On August 4, 2026, the Ukrainian state non-profit company Radon Association received five modern support systems to enhance the uninterrupted operation capability of the Integrated Automated Radiation Monitoring System (IASRM). The project is financially supported by the European Union through the Science and Technology Center in Ukraine, pursuant to Agreement No. INSC/2023/442-610 signed on May 22, 2023. Under the contractual arrangements, the relevant equipment has been delivered to the regional branches of the Radon Association and the central production base branch, with installation completed at the designated facilities. The systems installed this time mainly include backup power supply equipment such as diesel generators, which can provide continuous power to IASRM equipment during main power interruptions or shutdowns, thereby ensuring the normal operation of the radiation monitoring system under abnormal power supply conditions.

2026-08-10

DNT "Radon Association" Receives EU Technical Assistance Equipment to Strengthen Radiation Dose Monitoring Capabilities

On August 4, 2026, under the framework of the EU International Technical Assistance Project, the DNT Radon Association received a batch of modern measurement equipment for radiation dose monitoring, aimed at enhancing radiation monitoring and dose control capabilities. The project is financially supported by the EU through the Science and Technology Center in Ukraine, pursuant to Donor Agreement No. 700001998 signed on June 24, 2024. In accordance with the contractual arrangements, the relevant measurement equipment has been delivered to the Association's interregional branches and central production base branches. Following delivery, the DNT Radon Association conducted acceptance testing of the supplied measurement equipment. The test results demonstrated that the equipment meets the requirements for its intended use. Concurrently, the Association also organized relevant personnel to undergo training in equipment operation and maintenance; upon completion of the training and knowledge assessment, the relevant experts were awarded certificates of completion.

2026-08-10

China's First Homegrown Radiopharmaceutical Receives Dual FDA Breakthrough Therapy and Fast Track Designations

On August 6, Nuoyu Medical announced that the U.S. Food and Drug Administration (FDA) has officially granted Breakthrough Therapy Designation (BTD) and Fast Track Designation (FTD) to the company's independently developed 68Ga-NYM096. This marks the first product in China's original radiopharmaceutical field to receive FDA Breakthrough Therapy Designation, and the first to receive both FDA Breakthrough Therapy and Fast Track designations simultaneously, creating a milestone breakthrough in the radiopharmaceutical field. 68Ga-NYM096 is a small-molecule diagnostic radiopharmaceutical for renal cancer that specifically binds to CAIX, suitable for positron emission tomography (PET) imaging of suspected or confirmed metastatic clear cell renal cell carcinoma (c...

2026-08-08